Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Follow-Up Questions
Qui est le CEO de Sequana Medical NV ?
Ian Crosbie est le Chief Executive Officer de Sequana Medical NV, il a rejoint l'entreprise depuis 2019.
Quelle est la performance du prix de l'action SQNMF ?
Le prix actuel de SQNMF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Sequana Medical NV ?
Sequana Medical NV appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Sequana Medical NV ?
La capitalisation boursière actuelle de Sequana Medical NV est de $NaN
Est-ce que Sequana Medical NV est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour Sequana Medical NV, y compris 4 achat fort, 4 achat, 2 maintien, 0 vente et 4 vente forte
